secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001628280-24-034110
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M
----------------------------------------------------------------------------

- IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.
- Total revenue $73.2M vs $22.3M YoY; net loss narrowed to $16.5M ($0.07/sh) from $17.1M ($0.08/sh) YoY.
- FY 2024 IBSRELA revenue guidance unchanged at $140-150M; cash and investments $186M at quarter end.
- Filed lawsuit against CMS over ESRD PPS rule threatening XPHOZAH access; declined TDAPA application.
- SG&A expenses doubled to $64.7M primarily due to ongoing commercialization of both products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024034110/0001628280-24-034110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024034110/ardx-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer